Global Expansion Vyluma is a small biopharmaceutical ophthalmic player actively pursuing international commercialization through licensing partnerships in Canada, Mexico, South America, China, and Southeast Asia, signaling a strong channel for partner-driven sales and regional market entry opportunities.

Strategic Partnerships Existing and announced collaborations with Laboratoires Théa, Zhaoke Ophthalmology, and Thea Asia indicate a proven path to accelerate product registration and market access, presenting a ready-made blueprint for co-development and distribution deals for NVK002.

Product Focus NVK002 appears to be a core asset aimed at refractive error treatment, suggesting a niche ophthalmic portfolio ripe for ophthalmology-focused distributors, clinics, and specialty retailers seeking differentiated ophthalmic solutions.

Publicity & Visibility Participation in high-profile events like the JP Morgan Healthcare Conference and ongoing press coverage signal growing visibility; leverage investor and industry attention to open introductions with large ophthalmology networks and potential strategic buyers.

Technology & Compliance Adoption of cloud and web tech with standard security measures demonstrates a modern digital footprint; this can form the basis for scalable digital marketing, partner portals, and compliant data sharing with distributors and contract manufacturers.